Significant advancements in understanding the molecular and cellular mechanisms of tumor progression have been made, yet challenges remain.
Q3 2024 update: artificial intelligence related private equity activity in the pharmaceutical industry
In value terms, artificial intelligence-related deal activity increased by 50% in Q3 2024 compared with the previous quarter’s total of $2.8m and fell by 100%